Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA3 | P07451 | 2/20 | 0.49 |
| ▸ | CA6 | P23280 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679497 | 0.90 | CA12 (0.51) | CA12CA2CA3CA6CA7 | |
| SCHEMBL18752283 | 0.90 | CA12 (0.53) | CA12CA2CA3CA6CA7 | |
| SCHEMBL14652631 | 0.89 | F2 (0.54) | CA12CA2CA3CA6CA7 | |
| SCHEMBL7682282 | 0.87 | F2 (0.63) | CA12CA2CA3CA6CA7 | |
| SCHEMBL18752303 | 0.87 | CA12 (0.37) | CA12CA2CA3CA6CA7 | |
| SCHEMBL14652644 | 0.85 | F2 (0.48) | CA12CA2CA3CA6CA7 | |
| SCHEMBL7681986 | 0.85 | POLB (0.47) | CA12CA2CA3CA6CA7 | |
| SCHEMBL7675695 | 0.84 | MAOB (0.53) | CA12CA2CA3CA6CA7 | |
| SCHEMBL14642387 | 0.83 | F2 (0.58) | CA12CA2CA3CA6CA7 | |
| SCHEMBL18752216 | 0.81 | CA12 (0.56) | CA12CA2CA3CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814696-B2 | Use of coumarin derivatives for the preparation of drugs for treating skin diseases | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2017-11-14 | — | — | US | disclosed |
| US-9814696-B2 | Use of coumarin derivatives for the preparation of drugs for treating skin diseases | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2017-11-14 | — | — | US | disclosed |
| EP-2731604-B1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIV PIERRE ET MARIE CURIE PARIS 6 (FR) | 2017-04-19 | — | — | EP | disclosed |
| US-20170065555-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIVERSITE DE LIEGE (BE) | 2017-03-09 | — | — | US | disclosed |
| US-20170065555-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIVERSITE DE LIEGE (BE) | 2017-03-09 | — | — | US | disclosed |
| US-9532973-B2 | Use of coumarin derivatives for the preparation of drugs for treating skin diseases | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2017-01-03 | — | — | US | disclosed |
| US-20150182499-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIVERSITE DE LIEGE (BE) | 2015-07-02 | — | — | US | disclosed |
| US-20150182499-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIVERSITE DE LIEGE (BE) | 2015-07-02 | — | — | US | disclosed |
| US-9006466-B2 | Use of coumarin derivatives for the preparation of drugs for treating skin diseases | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2015-04-14 | — | — | US | disclosed |
| US-9006466-B2 | Use of coumarin derivatives for the preparation of drugs for treating skin diseases | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2015-04-14 | — | — | US | disclosed |
| US-20140148480-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2014-05-29 | — | — | US | disclosed |
| US-20140148480-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2014-05-29 | — | — | US | disclosed |
| WO-2013010963-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2013-01-24 | — | — | WO | disclosed |
| EP-2545916-A1 | Use of coumarin derivatives for the preparation of drugs for treating skin diseases | Universite Pierre Et Marie Curie - Paris 6 (FR) | 2013-01-16 | — | — | EP | disclosed |
| US-6355658-B1 | COUMARIN ESTERS WITH ETHER GROUPS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148480-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | BDKRB1, KLK1, SERPINC1 | CA12 1833/4885CA2 1907/4885CA3 2248/4885 |
| US-20150182499-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | BDKRB1, SERPINC1, KLK1 | CA12 1833/4885CA2 1935/4885CA3 2274/4885 |
| US-20170065555-A1 | USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES | BDKRB1, SERPINC1, KLK1 | CA12 1833/4885CA2 1935/4885CA3 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.